Clinical implications of novel polymer and lipid based drug delivery systems

Kallem Sharat Venkat Reddy*

Department of Pharmacy Practice, Bharat Institute of Technology, Hyderabad, Telangana, India.

ABSTRACT

The use of lipids in drug delivery is not a new trend, some of the lipid dosage forms have been in use for a long time such as suppositories, creams, and emulsions. However, there has been much advancement in the designs of lipid carriers over the past decade. In the same way from the past two decades, new approaches in biodegradable and bio-reducible polymers have paved a way for many recent drug delivery systems. Applications of these novel drug delivery formulations have been promising clinically. However, each system has its pros and cons in various factors depending upon their use and intended route of administration. This review focuses on upbringing the challenges in the use of novel lipid and polymer drug delivery systems in clinical settings and few insights on how to overcome them.

Keywords: Novel drug delivery; Gene delivery; Liposomes; Polymerosomes; Solid dispersions.

INTRODUCTION

In pharmaceutical technology, lipids and polymers have always been the vital components of drug delivery and dosage forms [1]. They can be used in many ways such as stabilizers, solubilizers, permeation enhancers, release rate modifiers, and also targeted systems. In the early day’s lipids and polymers were derived from various natural sources but with advancements and development in chemistry, the drug formulators now use a variety of natural, semi-synthetic, and also completely man-made lipids and polymers manufactured in various types for use in different routes such as oral, topical, etc. Lipids and polymers have similar roles despite their structural differences and quality by design approach is followed to ensure safety of product [2]. New applications of lipids in fields such as gene therapy and new methods of improving circulation in the body blood flow by stabilization are also being proven efficient [3].

Novel lipid-based nanoformulations such as nanostructured lipid carriers and solid lipid nanoparticles have been proven to be a recent breakthrough in many aspects. Nanofibres that are manufactured through electrospinning are also proving to be efficient in cancer diagnosis, tissue engineering etc [4,5,6]. However, when it comes to usage of these drug delivery systems through various routes in real-time clinical settings and hospitals, few challenges need to be addressed [7]. Certain side effects and adverse outcomes are being reported by the usage of these novel drug delivery systems in clinical settings. Although many of these drug delivery systems reach the clinical trials phase, some of them don’t show expected and desirable results and can’t succeed the phase 4 of clinical trials. Certain steps are followed by manufacturers to ensure the safety of using these drug delivery systems. High-performance liquid chromatography (HPLC) is used for the analysis [8,9,10].

Novel lipid based drug delivery systems

The main objective of using lipid-based drug delivery systems is to improve the bioavailability and to promote better solubility as well as the distribution of poor water-soluble drugs [11]. Lipid-based formulations can be efficiently designed to meet many requirements such as solubility, cost-efficacy, bioavailability, route of administration, and toxicity. Lipid-based drug delivery system can be used for routes including oral, topical, vaginal, parental, ocular, and also intranasal. For example proliposomal gel is used for rheumatoid arthritis for sustained
release of drug. However the most preferred route is oral. A recent novel approach for the oral lipid drug delivery system is lipid nanocarriers. The recent developments are in motion in solid lipid nanoparticles (SLN’s), Nanostructured lipid carriers (NLCs), Lipid drug conjugate (LDCs), Self nanoemulsifying drug delivery system (SNEDDS) [14,15,16]. These nanoparticles have opened up a way for the treatment of cancer through options such as gene therapy through siRNA. High Profile Liquid Chromatography is used for quantitative and qualitative isolation of lipids. The main exponents for lipid-based formulations are: 1) Solubility, 2) Dispersion, 3) Digestion, 4) Absorption. [17,19]

**Trends in novel lipid based drug delivery systems**

Recent technological advancements in medicine and discoveries in pharmacology have made possible many new lipid-based drug delivery systems and paved a way for efficient treatment methods for cancers too [19]. Lipid-based drug delivery systems are nowhere to be considered as new because they have been in use for a very long time. But recent and main advancements have occurred over the past decade with breakthrough discoveries. [20]

Recent trends in the lipid-based drug delivery systems are nano particles with limelight focused upon solid lipid nanoparticles and nanostructured lipid carriers [21,22]. These two along with hybrid nanoparticles have gained much interest as drug delivery systems because of their capacity to hold and release drugs of Class 2 (High Permeability and Low Solubility) [23] and Class 4 (Low Permeability and Low Solubility) [24] from the Biopharmaceutical Classification System (BCS). Many novel liposomal drug formulations are already in late-stage clinical trials for cancer treatment as they have been proven effective in improving the efficacy and safety of chemotherapeutic agents for cancer treatment. [25]

Specific targeted drug delivery is the main goal for any discovery and that is made possible by temperature-sensitive liposomes (TSL’s) that helps in minimizing the clearance and non-specific uptake. ThermoDox (Celsius) is showing promising results in drug uptake and release rate in heated tumors. Magnetic resonance-guided focused ultrasound is being combined with TSL to promote better efficacy of localized chemotherapy. Prolopopisomes, defined as free flowing particles in a dispersed system can immediately convert into liposomal suspension as soon as it comes in contact with water. [26,27,28] Nanocarrier based delivery of platinum compounds for cancer treatment in the field with most extensive research and clinical trials under progress which would revolutionize the platinum chemotherapy. Some other innovations of lipids are, nanofibres which bought a revolution in tissue engineering. Also nano ethosomes which carry bioactive agents and help penetrate them deep into the layers of skin. [29]

**Novel polymer based drug delivery systems**

Polymer-based drug delivery systems have gained major advancements in the past two decades. It can be defined as a formulation used to introduce a drug into the body. Biodegradable and bio reducible polymers have made possible a choice for many new drug delivery systems. [30] For polymer-based drug delivery systems natural polymers such as polysaccharides, dextrin, chitosan (obtained from shellfish) [31], arginine, alginate (derived from brown seaweed known as Phaeophyceae), Zein (found in corn) and hyaluronic acid are used. Synthetic polymers such as dendrity polymers, 2-hydroxyethyl methacrylate, PLGA (elastomeric copolymer) and N-isopropyl acrylamide are used. Targeting polymeric drug delivery and biomimetic and bio-related polymeric systems are also used in polymeric based drug delivery. [32,33,34] The polyethyleneimine derivatives are used as a system for non-viral vectors for gene delivery also polyethyleneimine copolymer. Polyvinylpyrrolidone (PVP) is also being studied as excipient from conventional to controlled delivery systems for COVID-19 inhibition. [35] Systems for viral vectors are DNA conjugates and RNA conjugates for gene delivery. In situ gel is an effective polymer based drug delivery system for ophthalmic purposes. [36]

**Trends in novel polymer based drug delivery systems**

Smart polymers can be said as the current breakthrough in the drug delivery system from the past decade. The ultimate aim for a manufacturer of any drug or any invention of formulation and drug delivery system is to provide a site-specific or targeted drug for anything, recent advancements in the polymeric drug delivery system have made this possible. For example Alginate is multifunctional with its uses ranging from impression making in dentistry and also in preparation of reflux inhibiting medications. [37,38] Zein another natural polymer is used for targeted drug delivery, gene delivery and also vaccinations. Smart polymers are gaining momentum, and researchers are interested as the discoveries in the chemistry by scientists are paving a way for innovation of controlled release drug systems and drugs that sense environmental and biological changes. [39,40] The smart polymers such as pH-sensitive polymers, temperature-sensitive polymers, polymers with dual stimuli responsiveness, phase-sensitive polymers, and light-sensitive smart polymers are the major discoveries in the past 10 years that made possible a ton of new efficient ways for treatment. Biomimetic and bioinspired systems are used to improve the biocompatibility during drug delivery. [41] Dendrimers, these polymers with well defined molecular weight and multi-branching are showing promising results for further aspects of polymeric drug delivery systems. The viral and non-viral vectors for polymeric gene delivery are promising for cancer treatment and have the potential to be an important tool for human gene therapy too. Okra
thioglycolic acid is used as a mucoadhesive polymer and is multifunctional.[42] Chitosan a naturally obtained polymer is also proven to be effective in weight loss. [43]

Clinical implications by using lipid/ polymer drug delivery systems

Although Lipid and Polymeric drug delivery systems are considered as one of the greatest advancements in the past decade there are many challenges when it comes to real-time clinical setting. Many of these new delivery systems are not being successful in phase 4clinical trials. [44,45]

Disadvantages and limitations of lipid based drug delivery systems

Every system has pros and cons to go with. There are certain disadvantages for lipid-based drug delivery systems, some of them are:

1. **API Instability**: API Instability is seen in certain formulations; research is still ongoing to consider the factors that promote API stability. [46]
2. **Excipient shell compatibility issues**: This compatibility issues and interactions may have effects on bioavailability, stability, and chemical also physical factors of the drug or dosage. [47,48]
3. **Uncontrolled drug precipitation post-dosing**: This may have normal therapeutic failure or serious effects on the patients by either embolization ranging from thrombophlebitis or multiple organ failure and even death. [49]
4. **Inadequate drug loading in the lipid drug delivery system**: This is also a major setback in the formulation of the lipid-based drug delivery system which may lead to inefficient therapeutic effects. [50, 51]
5. **Drug burst release by erosion mechanism.** [52]
6. **Drug expulsion.** [45]
7. **Accumulation of lipids in the liver and spleen may cause pathological alteration with certain lipid nanoparticles.** [53]
8. **Enhanced permeability and retention effect (EPR) may vary significantly from one human patient to another.** [4]

Disadvantages and limitations of polymeric based drug delivery systems

1. **Insufficient literature of toxicological assessment**[54]
2. **Can be only used for lipophilic drugs** [55]
3. **Low drug loading capacity** [56]
4. **Elimination and mechanism depending upon the materials and generation** [57,58]
5. **High cost for their synthesis** [52]
6. **Chances of cellular toxicity** [36]
7. **Difficult to maintain the integrity of synthetic and natural polymers in the body in genetic engineering or in vivo treatments** [54]
8. **Complex and multistep process** [38, 52]

Safety, efficacy, and success rate of lipid and polymer based drug delivery system

The new approaches to drug delivery system in terms of polymer and lipid-based are successful in the clinical trials phase with in vivo and genetic engineering advancements. [56] Post-marketing surveillance report, however, vary in some of these drug delivery systems as the EPR and other factors vary from human to human and also a lot of other factors needs to be characterized to formulate a successful system that works for all the humans similarly. [59] To ensure the safety of these drug delivery systems the formulators and manufacturers make sure to strike off the factors that may arise any further complications. [60] However more literature and more trials need to be done to determine the factors that may promote or demote the efficacy of the drug in the patients and prevent any unwanted adverse effects.

CONCLUSION

Since their discovery lipids and polymers have advanced rapidly technologically from being used as an apparatus for cell membranes to versatile drug carriers. These drug delivery systems have emerged as a promising strategy for new-age drug delivery systems including potential cancer treatment. Many formulations are being investigated in different phases of clinical trials and awaiting approval while many others are already been approved and commercially available. However, the post surveillance reports show certain setbacks. Further studies and clinical trials are warranted to completely optimize their potential as drug delivery systems and to overcome the setbacks and challenges these two drug delivery systems are facing in the real-time clinical settings.

REFERENCES

1. Dahan, A., & Hoffman, A. (2008). Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Journal of controlled release, 129(1), 1-10.
2. Ahmed, O. A. A., Kurakula, M., Banjar, Z. M., Afouna, M. I., &Zidan, A. S. (2015). Quality by design coupled with near infrared in formulation of transdermal glimepiride liposomal films. Journal of Pharmaceutical Sciences, 104(6), 2062–2075. https://doi.org/10.1002/jps.24448.
3. Kalepu, S., Manthina, M., &Padaval, V. (2013). Oral lipid-based drug delivery systems—an overview. Acta Pharmaceutica Sinica B, 3(6), 361-372.
4. Murali, V. P., Fujiwara, T., Gallop, C., Wang, Y., Wilson, J. A., Atwill, M. T., Kurakula, M., & Bumgardner, J. D. (2020). Modified electrospun chitosan membranes for controlled release of simvastatin. International Journal of
Pharmaceutics, 584, 119438. https://doi.org/10.1016/j.ijpharm.2020.119438

5. Abdelhady, S., Hosny, K. M., & Kurakula, M. (2015). Electro Spun- Nanofibrous Mats: A Modern Wound Dressing Matrix with a Potential of Drug Delivery and Therapeutics. Journal of Engineered Fibers and Fabrics, 10 (4), 155892501501000. https://doi.org/10.1177/155892501501000411

6. Chen, J., Ansell, S., Akin, A., Dorkin, J. R., Qin, X., Cantley, W., & Jayaraman, M. (2012). U.S. Patent No. 8,150,601. Washington, DC: U.S. Patent and Trademark Office.

7. Xiao, H., Yan, L., Dempsey, E. M., Song, W., Qi, R., Li, W., & Chen, X. (2018). Recent progress in polymer-based platinum drug delivery systems. Progress in Polymer Science, 87, 70-106.

8. Kurakula, M., Mohd, A. B., A, P. R., & Diwan, P. V. (2011a). Estimation of Prednisolone in Proliposomal formulation using RP HPLC method. Int. J. Res. Pharm. Biomed. Sci. 2011; 2: 663, 2(4), 1663–1669.

9. Kurakula, M., Sobahi, T. R., El-Helw, A., & Abdelaal, M. Y. (2014). Development and validation of a RP-HPLC method for assay of atorvastatin and its application in dissolution studies on thermosensitive hydrogel-based nanocrystals. Tropical Journal of Pharmaceutical Research, 13(10), 1681–1687. https://doi.org/10.4314/tjpr.v13i10.16.

10. Kurakula, M., Mohd, A. B., Rao, P. A., & Diwan, P. V. (2011). Estimation of piroxicam in proliposomal formulation using RP HPLC method. Int. J. Chem. Anal. Sci. 2011; 2: 1193, 1196.

11. Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013). Nanocarriers for delivery of platinum anticancer drugs. Advanced drug delivery reviews, 65(13-14), 1667-1685.

12. Kurakula, M., Srinivas, C., Kasturi, N., & Diwan, P. V. (2012). Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. International Journal of Pharmaceutical Sciences and Drug Research, 4(1), 35.

13. Mallesh, K., Pasula, N., & Kumar Ranjith, C. P. (2012). Piroxicam proliposomal gel: a novel approach for tropical delivery. Journal of Pharmacy Research, 5(3), 1755–1763.

14. Min, Y., Mao, C. Q., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012). Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angewandte Chemie, 124(27), 6846-6851.

15. Hosny, K. M., Al-Dawsari, H. M., Bahmdan, R. H., Sindi, A. M., Kurakula, M., Alrobaian, M. M., Aldryhim, A. Y., Alkhali, H. M., Bahmdan, H. H., Khallaf, R. A., & El Sisi, A. M. (2019). Preparation, Optimization, and Evaluation of Hyaluronic Acid-Based Hydrogel Loaded with Miconazole Self-Nanoemulsion for the Treatment of Oral Thrush. AAPS PharmSciTech, 20(7), 297. https://doi.org/10.1208/s12249-019-1496-7.

16. Vanitasagar, S., Srinivas, C., Subhashini, N. J. P., & Mallesh, K. (2012). Solid dispersion-a comparative study on the dissolution rate of acedofenac. International Journal of Pharmacy and Pharmaceutical Sciences, 4(SUPPL.3), 274–278.

17. Venkatesh, M., & Mallesh, K. (2013). Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of atorvastatin-formulation and bioavailability studies. Journal of Drug Delivery and Therapeutics, 3(3), 131-140.

18. Mazzafarrelo, S., Bouchenal, K., & Ponchet, G. (2013). Oral delivery of anticancer drugs III: formulation using drug delivery systems. Drug discovery today, 18(1-2), 99-104.

19. Developing Lipid-Based Formulations (https://www.pharmtech.com/view/developing-lipid-based-formulations)

20. Mora-Huertas, C. E., Fessi, H., & Elaissari, A. (2010). Polymer-based nanocapsules for drug delivery. International journal of pharmaceutics, 385(1-2), 113-142.

21. Raghavendra Naveen, N., Kurakula, M., & Gowthami, B. (2020). Process optimization by response surface methodology for preparation and evaluation of methotrexate loaded chitosan nanoparticles. Materials Today: Proceedings. https://doi.org/10.1016/j.matpr.2020.01.491.

22. Shapland, J. E., Hildebrand, K. R., Racchini, J. R., Shimada, J., & Knudson, M. B. (1998). U.S. Patent No. 5,807,306. Washington, DC: U.S. Patent and Trademark Office.

23. Naguib, Ghada Hussein, Al-Hazmi, F. E., Kurakula, M., Abdulaziz Al-Dharrab, A., Mohamed Hosny, K., Mohammed Alkhali, H., Tharwat Hamed, M., Habiballah Hassan, A., Al-Mohamadi, A. M., Mohamed Alnowaiser, A., & Henry Pashley, D. (2018). Zein coated zinc oxide nanoparticles: Fabrication and antimicrobial evaluation as dental aid. International Journal of Pharmacoogy, 14(8), 1051-1059. https://doi.org/10.3923/ijp.2018.1051.1059.

24. Sahatjian, R. (1994). U.S. Patent No. 5,304,121. Washington, DC: U.S. Patent and Trademark Office.

25. Liechty, W. B., Kryscio, D. R., Slaughter, B. V., & Peppas, N. A. (2010). Polymers for drug delivery reviews, 65(13-14), 1667-1685.
26. Kurakula, M., Ahmed, O. A. A., Fahmy, U. A., & Ahmed, T. A. (2016). Solid lipid nanoparticles for transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo studies. Journal of Liposome Research, 26(4), 288–296. https://doi.org/10.3109/08982104.2015.1117490

27. Son, G. H., Lee, B. J., & Cho, C. W. (2017). Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles. Journal of Pharmaceutical Investigation, 47(4), 287-296.

28. Veerapu, G., Gangadharappa, H. V., Nagashubha, B., & Balamuralidhara, V. (2014). Review on novel carrier system: liposomes and proliposomes. Drug Delivery Letters, 4(2), 96-109.

29. Kurakula, M., & Koteswara Rao, G. S. N. (2020). Moving polyvinyl pyrrolidone electrospun nanofibers and bioprinted scaffolds toward multidisciplinary biomedical applications. European Polymer Journal, 136, 109919. https://doi.org/10.1016/j.eurpolymj.2020.109919.

30. Kurakula, M., Naveen, N. R., & Yadav, K. S. (2020). Formulations for Polymer Coatings. Polymers Coatings: Technology and Applications, 415.

31. Alhakamy, N. A., Ahmed, O. A. A., Kurakula, M., Caruso, G., Caraci, F., Asfour, H. Z., Alfarsi, A., Eid, B. G., Mohamed, A. I., Alruwaili, N. K., Abdulal, W. H., Fahmy, U. A., Alhadrami, H. A., Eldakhakhny, B. M., & Abdel-Naim, A. B. (2020). Chitosan-based microparticles enhance elagic acid’s colon targeting and proapoptotic activity. Pharmaceutica, 12(7), 1–14. https://doi.org/10.3390/pharmaceutics12070652.

32. Kurakula, M., & A Ahmed, T. (2016). Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for anti-hyperlipidemic efficacy. Current Drug Delivery, 13(2), 211-220.

33. Kurakula, M., El-Helw, A. M., Sobahi, T. R., & Abdelal, M. Y. (2015). Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vitro efficacy. International journal of nanomedicine, 10, 321.

34. Hasnain, M. S., Kiran, V., Kurakula, M., Rao, G. K., Tabish, M., & Nayak, A. K. (2020). Use of alginates for drug delivery in dentistry. In Alginates in Drug Delivery (pp. 387–404). Elsevier. https://doi.org/10.1016/b978-0-12-817640-5.00015-7.

35. Kurakula, M., & Rao, G. S. N. K. (2020). Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. Journal of Drug Delivery Science and Technology, 60, 102046. https://doi.org/10.1016/j.jddst.2020.102046.

36. Kurakula, M., & Raghavendra Naveen, N. (2020). In situ gel loaded with chitosan-coated simvastatin nanoparticles: Promising delivery for effective anti-proliferative activity against tongue carcinoma. Marine Drugs, 18(4), 201. https://doi.org/10.3390/md18040201.

37. Hasnain, M. S., Nayak, A. K., Kurakula, M., & Hoda, M. N. (2020). Alginate nanoparticles in drug delivery. In Alginates in Drug Delivery (pp. 129–152). Elsevier. https://doi.org/10.1016/b978-0-12-817640-5.00006-6.

38. Kurakula, M., Rao, G. K., Kiran, V., Hasnain, M. S., & Nayak, A. K. (2020). Alginate-based hydrogel systems for drug releasing in wound healing. In Alginates in Drug Delivery (pp. 323–358). Elsevier. https://doi.org/10.1016/b978-0-12-817640-5.00013-3.

39. Naguib, G. H., Hassan, A. H., Al-Hazmi, F., Kurakula, M., Al-Dharrah, A., Alkalidi, H. M., Al-Ahdal, A. M., Hamed, M. T., & Pashley, D. H. (2017). Zein based magnesium oxide nanowires: Effect of anionic charge on size, release and stability. Digest Journal of Nanomaterials and Biostructures, 12(3), 741–749.

40. Rao, G. K., Kurakula, M., & Yadav, K. S. (2020). Application of Electrospun Materials in Gene Delivery. Electrospun Materials and Their Allied Applications, 265-306. https://doi.org/10.1002/9781119655039.ch10.

41. Park, T. G., Cohen, S., & Langer, R. S. (1994). U.S. Patent No. 5,330,768. Washington, DC: U.S. Patent and Trademark Office.

42. Naveen, N. R., Gopinath, C., & Kurakula, M. (2020). Okra-thioglycolic acid conjugate-synthesis, characterization, and evaluation as a mucoadhesive polymer. Processes, 8(3), 316. https://doi.org/10.3390/pr8030316.

43. Alhakamy, N. A., Fahmy, U. A., Ahmed, O. A. A., Caruso, G., Caraci, F., Asfour, H. Z., Bakhrehab, M. A., Alomary, M. N., Abdulal, W. H., Okbazghi, S. Z., Abdel-Naim, A. B., Eid, B. G., Aldawsari, H. M., Kurakula, M., & Mohamed, A. I. (2020). Chitosan coated microparticles enhance simvastatin colon targeting and pro-apoptotic activity. Marine Drugs, 18(4), 226. https://doi.org/10.3390/md18040226.

44. Pattewar, S., Kasture, S., Pande, V., & Sharma, S. (2016). Self microemulsifying drug delivery system: A lipid based drug delivery system. International Journal of Pharmaceutical Sciences and Research, 7(2), 443.
45. Asadujjaman, M. D., & Mishuk, A. U. (2013). Novel approaches in lipid based drug delivery systems. Journal of Drug Delivery and Therapeutics, 3(4), 124-130.

46. Bally, M. B., Lim, H., Cullis, P. R., & Mayer, L. D. (1998). Controlling the drug delivery attributes of lipid-based drug formulations. Journal of Liposome Research, 8(3), 299-335.

47. Langer, R. (1993). Polymer-controlled drug delivery systems. Accounts of chemical research, 26(10), 537-542.

48. Liu, Y., & Liu, J. (2020). Leakage and Rupture of Lipid Membranes by Charged Polymers and Nanoparticles. Langmuir, 36(3), 810-818.

49. Zalipsky, S., Woodle, M. C., Lasic, D. D., & Martin, F. J. (1995). U.S. Patent No. 5,395,619. Washington, DC: U.S. Patent and Trademark Office.

50. Schultz, H. B., Thomas, N., Rao, S., & Prestidge, C. A. (2018). Supersaturated silica-lipid hybrids (super-SLH): An improved solid-state lipid-based oral drug delivery system with enhanced drug loading. European Journal of Pharmaceutics and Biopharmaceutics, 125, 13-20.

51. Wang, G., Wang, J., Wu, W., Tony To, S. S., Zhao, H., & Wang, J. (2015). Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert opinion on drug delivery, 12(9), 1475-1499.

52. Aburahma, M. H., & Badr-Eldin, S. M. (2014). Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert opinion on drug delivery, 11(12), 1865-1883.

53. Adams, D., Gonzalez-Duarte, A., O’Riordan, W.D., Yang, C.-C., Ueda, M., Kristen, A.V., Tourneve, I., Schmidt, H.H., Coelho, T., Berk, J.L., Lin, K.-P., Vita, G., Attarian, S., Planté-Bordeneuve, V., Mezei, M.M., Campistol, J.M., Buades, J., Brannagan, T.H., Kim, B.J., Oh, J., Parman, Y., Sekijima, Y., Hawkins, P.N., Solomon, S.D., Polydefkis, M., Dyck, P.J., Gandhi, P.J., Goyal, S., Chen, J., Strachs, A.L., Nochur, S.V., Sweetser, M.T., Garg, P.P., Vaishnaw, A.K., Gollob, J.A., Suhr, O.B., 2018. Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis. New Engl. J. Med. 379, 11–21.

54. Ahmed, F., Pakunlu, R. I., Brannan, A., Bates, F., Minko, T., & Discher, D. E. (2006). Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. Journal of Controlled Release, 116(2), 150-158.

55. DeVincenzo, J., Cehelsky, J. E., Alvarez, R., Elbashir, S., Harborth, J., Toudjarska, I., & Meyers, R. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral research, 77(3), 225-231.

56. Griesser, J., Hetényi, G., Kadas, H., Demarne, F., Jannin, V., & Bernkop-Schnürch, A. (2018). Self-emulsifying peptide drug delivery systems: How to make them highly mucus permeating. International Journal of Pharmaceutics, 538(1-2), 159-166.

57. Siepmann, J., Faham, A., Clas, S. D., Boyd, B. J., Jannin, V., Bernkop-Schnürch, A., ..., & Merkel, O. M. (2019). Lipids and polymers in pharmaceutical technology: Lifelong companions. International journal of pharmaceutics, 558, 128-142.

58. Friesen, D. T., Shanker, R., Crew, M., Smithey, D. T., Curato, W. J., & Nightingale, J.A.S. (2008). Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Molecular pharmaceutics, 5(6), 1003-1019.

59. O’Driscoll, C. M., Bernkop-Schnürch, A., Friedl, J. D., Préat, V., & Jannin, V. (2019). Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?. European Journal of Pharmaceutical Sciences, 133, 190-204.

60. Zaichik, S., Steinbring, C., Caliskan, C., & Bernkop-Schnürch, A. (2019). Development and in vitro evaluation of a self-emulsifying drug delivery system (SEDDS) for oral vancomycin administration. International journal of pharmaceutics, 554, 125-133.